Investors & Media Home

Mesoblast is a world leader in cell-based medicines.

The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.

These allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, orthopedic disorders, oncology and... More

Latest ASX AnnouncementsMore
09 September 2016
Change of Melbourne Registry Address Notification
01 September 2016
Mesoblast Appoints Bill Burns As Vice Chairman
25 August 2016
Mesoblast Reports on Annual and Fourth Quarter Results
25 August 2016
Annual Financial Results Presentation
Latest Press ReleasesMore
24 February 2016
First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee
NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MES... 
22 February 2016
Increased Survival Using MSB Cells In Children With aGVHD
17 February 2016
Mesoblast Reports on First Half and Second Quarter Financial Results
MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (... 
16 February 2016
MSB Therapy Shows Benefit In First Cohort Of RA Patients
Upcoming EventsMore
There are currently no events scheduled.
Stock QuoteMore
Exchange :ASX
Price :A$1.11
Change : Stock is Down 0.01 (0.89%)
Volume :816,563
Data as of 23 September 2016 4:11 p.m. ET
Data provided by Nasdaq Minimum 15 minutes delay
Download Documentation 2016 Full Year Results
Download Documentation Third Quarter 2016 Financial Results
Download Documentation Second Quarter 2016 Financial Results
E-mail Alerts
Sign up to receive e-mail alerts.

Share Price ASX: MSB  AUD 1.11 as of Sep 23, 2016